New pre-transplant drug combo for relapsed or refractory AML
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new combination of medicines (called MTBF) given before a donor stem cell transplant. It is for people with acute myeloid leukemia (AML) that has not gone away or has come back. The goal is to see if this approach is safe and helps control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have acute myeloid leukemia (AML) that has not responded to treatment or has returned after treatment.
- You have tried at least two standard chemotherapy treatments without success, or your leukemia came back within a year.
- You are able to undergo a donor stem cell transplant (also called allogeneic transplant).
- You do not have serious heart problems, active infections like hepatitis B or C, HIV, or another cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
This trial tests a combination of a new drug (SHR2554) with another medication (azacitidine) and a conditioning regimen before a stem cell transplant. It aims to improve outcomes for high-risk or relapsed leukemia and MDS patients.
This clinical trial tests a new combination of chemotherapy drugs (called TmBU) before a stem cell transplant for people with high-risk or relapsed acute leukemia. The goal is to see if this conditioning regimen works better and is safe for patients who need a transplant.
This trial tests a stem cell transplant (using donor cells) for people with a high-risk form of acute myeloid leukemia called CBF-AML. The goal is to see if this transplant can help patients who have a higher chance of the leukemia coming back.
This trial tests a combination of two drugs (SHR2554 and azacitidine) given before a stem cell transplant for people with high-risk or relapsed leukemia or MDS. The goal is to see if this approach can help make the transplant more effective and reduce the chance of the disease coming back.
This trial compares two drug combinations used before a stem cell transplant to see which is safer and more effective for people with acute myeloid leukemia (AML) that is in remission but still has minimal residual disease (MRD). The goal is to help prevent the leukemia from coming back after transplant.
Hear when a new Relapse Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.